<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="215584">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279019</url>
  </required_header>
  <id_info>
    <org_study_id>AC2103473</org_study_id>
    <nct_id>NCT00279019</nct_id>
  </id_info>
  <brief_title>Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomised, Double Blind, Placebo-controlled, Double Dummy, 4-way Cross-over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Inhaled Doses of GSK233705 and Tiotropium Bromide (18Âµg) Via DPI in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
      developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long
      duration of action of GSK233705 when administered via inhalation in animal models supports
      the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary
      disease.

      GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
      developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long
      duration of action of GSK233705 when administered via inhalation in animal models supports
      the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, blood pressure, heart rate, 12-lead electrocardiogram (ECG), Holter and Lead II ECG monitoring, ECG, lung function and clinical laboratory safety tests.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentrations of GSK233705 and derived pharmacokinetic parameters. Serial IOS and FEV1 measurements over 27 hours post-dose Serial sGaw, Raw measurements over 24 hours post-dose.</measure>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK233705</intervention_name>
    <description>Study Drug</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Of non-childbearing potential.

          -  Diagnosed with COPD, as defined by the GOLD guidelines.

          -  Smoker or an ex-smoker with a smoking history of at least 10 pack years.

          -  FEV1/FVC &lt; 0.7 post-bronchodilator (salbutamol).

          -  FEV1 &lt;= 80% of predicted normal for height, age and gender after inhalation of
             salbutamol.

          -  Response to ipratropium bromide 9.

          -  Subject's weight is 60kg.

        Exclusion criteria:

          -  Past or present disease, which as judged by the Investigator and the Medical Monitor,
             may affect the outcome of this study.

          -  FEV1 &lt;=50% of predicted after inhalation of salbutamol.

          -  Tested positive for hepatitis C antibody, hepatitis B surface antigen or HIV.

          -  Has claustrophobia that may be aggravated by entering the plethysmography cabinet.

          -  Has prostate hypertrophy or narrow angle glaucoma.

          -  Diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis,
             allergic rhinitis, or asthma.

          -  Poorly controlled COPD.

          -  Participated in a Pulmonary Rehabilitation Program within 4 weeks prior to screening
             visit or will enter a program during the study.

          -  Had a respiratory tract infection in the 4 weeks prior to the screening visit and
             throughout the duration of the study.

          -  History of congestive heart failure, coronary insufficiency or cardiac arrhythmia.

          -  A mean QTc(B) value at screening &gt;440msec, the QTc(B) of all 3 screening ECGs are not
             within 10% of the mean, a PR interval outside the range 120-210msec or an ECG that is
             not suitable for QT measurements.

          -  A history of elevated supine blood pressure or a mean blood pressure equal to or
             higher than 160/95 mmHg.

          -  A mean heart rate outside the range 40-90 bpm.

          -  QTc prolongation &gt;470msec or risk factors for torsades de pointes (heart failure NYHA
             II-IV, hypokalaemia, familial long QT syndrome).

          -  Receiving co-medication with drugs which prolong the QTc interval.

          -  Requires treatment with inhaled cromolyn sodium or nedocromil, oral beta-2-agonists,
             nebulised beta-2-agonists, nebulised anticholinergics or leukotriene modifiers.

          -  Unable to abstain from xanthines (other than caffeine.

          -  Unable to abstain from short-acting inhaled bronchodilators.

          -  Unable to abstain from long-acting inhaled bronchodilators.

          -  Changed dose of inhaled or oral corticosteroids within the last 6 weeks.

          -  Taking more than 10mg/day of prednisolone (or equivalent).

          -  Receiving treatment with long term or short-term oxygen therapy or requires nocturnal
             positive pressure for sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 22, 2016</lastchanged_date>
  <firstreceived_date>January 17, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK233705</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
